Immunoconjugates with an intracellularly-cleavable linkage

Methods and antibody compositions for tumor treatment

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof

Selective reduction of proteins

Serpin fusion polypeptides and methods of use thereof

BCMA binding molecules and methods of use thereof

Therapeutic immunoglobulin G4 for improved bioanalytical and bioprocessing properties

Heavy chain constant regions with reduced binding to Fc gamma receptors

NK cell engaging antibody fusion constructs

RECOMBINANT ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF

Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells

PDE5 compositions and methods for immunotherapy

Compositions and methods for treating cancer with anti-CD33 immunotherapy

ANTIBODY HEAVY CHAIN VARIABLE DOMAINS TARGETING THE NKG2D RECEPTOR

Engineered opsonin for pathogen detection and treatment

Monoclonal antibodies against c-Met

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

BCMA chimeric antigen receptors

CONJUGATE WITH ATTENUATED IMMUNE RESPONSE

Antibodies that bind to OX40 and their uses

Anti-LAG-3 antibodies and uses thereof

COMBINATION THERAPIES COMPRISING SIRP ALPHA-BASED CHIMERIC PROTEINS

FLT3L-based chimeric proteins

Modulation of cell function for immunotherapy

VARIANT TARGET BINDING AGENTS AND USES THEREOF

Methods of producing multispecific antibodies against CD40 and CD137

Anti-CD19 humanized antibody and immune effector cell targeting cd 19

Antibody capable of binding to norovirus, composite, detection device and method using the same

CHIMERIC ENGULFMENT RECEPTOR MOLECULES

Modified immunoglobulin hinge regions to reduce hemagglutination

BCMA and CD3 bispecific T cell engaging antibody constructs

Production of heterodimeric proteins

CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE

Modifying binding molecules to minimize pre-exisiting interactions

Binding molecules that bind CD137 and PD-L1

IMMUNOMODULATORY ANTIBODIES

MODULAR TETRAVALENT BISPECIFIC ANTIBODY PLATFORM

Anti-PDL1, IL-15 and TGF-beta receptor combination molecules

Chimeric transmembrane proteins and uses thereof

Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof

THE CONTORSBODY - A SINGLE CHAIN TARGET BINDER

BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy

Bispecific checkpoint inhibitor antibodies

Oncofetal antigen binding proteins and related compositions and methods

Bispecific checkpoint inhibitor antibodies

Anti-C5 antibodies and methods of treating complement-related diseases

CSF1R-CD40L chimeric proteins

Anti-HtrA1 antibodies and methods of use thereof

Anti-CD3 antibody and molecules comprising the antibody

TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains

Multivalent antibody

Bispecific IgG antibodies as T cell engagers

LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS

ASPARTATE BETA-HYDROXYLASE CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF

Folate receptor 1 antibodies and immunoconjugates and uses thereof

Fab molecules with a rodent hinge region and a non-rodent CH1 region

Cell engaging binding molecules

Polypeptide linker for preparing multispecific antibodies

Anti-human VISTA antibodies and use thereof

LAG-3 binding members

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS

CD229 CAR T cells and methods of use thereof

Tunable Chimeric Antigen Receptors

GHR-106 CHIMERIC ANTIGEN RECEPTOR CONSTRUCT AND METHODS OF MAKING AND USING SAME

Anti-MET antibodies and uses thereof

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS

Treatment of disease responsive to modulation of cannabanoid 1(CB1) receptor signaling

Cell engaging binding molecules

Cell engaging binding molecules

Antigen binding constructs to CD3

Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease

Anti-canine platelet derived growth factor receptor alpha antibody

B-CELL REDUCTION USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES

Compositions and methods related to engineered Fc constructs

USE OF ANTIBODY-COUPLED T CELL RECEPTOR (ACTR) WITH MULTIPLE ANTI-CANCER ANTIBODIES IN CANCER TREATMENT

COMPOSITIONS AND METHODS FOR T-CELL AND CYTOKINE ACTIVATION

Recombinant polypeptide production methods

Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity

Binding molecules binding PD-L1 and LAG-3

Antibodies directed against programmed death-1 (PD-1)

Heterodimeric antibodies that bind somatostatin receptor 2

Drug regulated transgene expression

Heavy chain only antibodies to ANG-2

Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof

BISPECIFIC FUSION POLYPEPTIDES AND METHODS OF USE THEREOF

Antibodies specific for CD70 and their uses

Single-domain antibodies and variants thereof against CTLA-4

Antibodies with reduced binding to process impurities

FLT3-specific chimeric antigen receptors and methods using same

Anti-LAG-3 antibodies and uses thereof

Triple vector for expressing antibody molecules in full therapeutic format

Long-Acting Therapeutic Fusion Proteins

Immunoglobulin constant region Fc receptor binding agents

IL-21 (heterodimeric Fc-fused IL-21) fused to immunoglobulin heavy chain constant region heterodimer (heterodimeric Fc), and pharmaceutical composition comprising same

Human CD3 binding antibody

ANTIBODY CONSTANT REGION VARIANT

Sequence symmetric modified IgG4 bispecific antibodies

Genetically-modified cells and method for producing same

EGFR binding molecules

GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE

Cysteine-optimized stradomers

Anti-4-1BB antibodies and their uses

Monovalent Asymmetric Tandem Fab Bispecific Antibodies

CHIMERIC ANTIGEN RECEPTORS AND METHODS FOR USE

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

Chimeric antigen receptor

Anti-CD40 antibodies

RECOMBINANT MONOVALENT ANTIBODIES AND METHODS FOR PRODUCTION THEREOF

Optimized PNE-based chimeric receptor T cell switches and uses thereof

Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease

CSF1R-based chimeric proteins

Immunoconjugates with an intracellularly-cleavable linkage

Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides

Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof

Anti-DEspR monoclonal antibody targeted therapy and imaging for cancer and stroke

Bispecific antibodies targeting EGFR and HER2

Modified chimeric antigen receptors and methods of use

Fc-region variants with improved protein A-binding

Multispecific antibody platform and related methods

Compositions for inhibiting MASP-2 dependent complement activation

Antibody fab and Fc variants

Heterodimeric proteins and methods for producing and purifying them

Multivalent and multispecific glucocorticoid-induced TNFR-related protein (GITR)-binding single-domain antibody fusion proteins and encoding nucleic acids

Covalent diabodies and uses thereof

Covalent Diabodies and Uses Thereof

Anti-interleukin-33 antibodies and uses thereof

Anti-Sialyl Tn chimeric antigen receptors

ANTI-IL-6 RECEPTOR ANTIBODY

Engineered immunoglobulin heavy chain-light chain pairs and uses thereof

NOVEL ANTI-CLAUDIN ANTIBODIES AND METHODS OF USE

Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases

Methods of treatment of CD123 overexpressing disorders

Recombinant human EPO-FC fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo

Antibodies against CD73 and uses thereof

Targeting tissue factor to activated platelets

Anti-CD30 chimeric antigen receptors

ANTIBODIES AGAINST CD73 AND USES THEREOF

Fusion proteins and their related methods

Anti-HtrA1 antibodies and methods of use thereof

DLL3 MODULATORS AND METHODS OF USE

Methods for selectively expanding and enriching cells transduced with chimeric antigen receptors and treating HIV infection

Nanoparticle compositions and methods for immunotherapy

FC-REGION VARIANTS WITH MODIFIED FCRN- AND MAINTAINED PROTEIN A-BINDING PROPERTIES

Oncofetal antigen binding proteins and related compositions and methods

FC-REGION VARIANTS WITH MODIFIED FCRN-BINDING PROPERTIES

METHOD OF MANUFACTURING BISPECIFIC ANTIBODIES, BISPECIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES

Bispecific T cell activating antigen binding molecules

Bispecific T cell activating antigen binding molecules

CD33 SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY

Caninized human antibodies to human IL-4R alpha

Antibodies comprising chimeric constant domains

CD38 antibody drug conjugate

NOVEL IMMUNOGLOBULIN VARIANTS

Chimeric antigen receptor cell preparation and uses thereof

Human monoclonal anti-PD-L1 antibodies and methods of use

Antibodies to canine interleukin-4 receptor alpha

SITE-SPECIFIC ANTIBODY CONJUGATION METHODS AND COMPOSITIONS

Antibodies comprising modified heavy constant regions

NOVEL ANTI-EMR2 ANTIBODIES AND METHODS OF USE

Immunomodulatory antibodies

ANTIBODY VARIANTS HAVING MODIFICATIONS IN THE CONSTANT REGION

Anti-CGRP/anti-IL-23 bispecific antibodies and uses thereof

Immunoconjugates with an intracellularly-cleavable linkage

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

Hinge modified antibody fragments and methods of making

Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof

HIDE1 COMPOSITIONS AND METHODS

SECRETORY TNT CAR CELL IMMUNOTHERAPY

Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy

MOLECULES WITH BIMODAL ACTIVITY DEPLETING TARGET AT LOW DOSE AND INCREASING IMMUNOSUPPRESSION AT HIGHER DOSE

Heavy chain constant regions with reduced binding to Fc gamma receptors

Anti-TIGIT anibodies, anti-PVRIG antibodies and combinations thereof

Compositions and methods for treating cancer with anti-CD33 immunotherapy

Chimeric antigen receptor to which anti-cotinine antibody is linked, and use thereof

CSGP4—specific chimeric antigen receptor for cancer

Anti-PD1 antibodies and their use as therapeutics and diagnostics

Non-human animals that select for light chain variable regions that bind antigen

Anti-PVRIG antibodies and methods of use

ANTI-LAG-3 ANTIBODIES TO TREAT HEMATOLOGICAL MALIGNANCIES

Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin Fc compositions with enhanced complement binding

Methods of making heavy chain only antibodies using transgenic animals

Human CD3 binding antibody

CD70 binding molecules and methods of use thereof

Kappa myeloma antigen chimeric antigen receptors and uses thereof

ScFv-Fc dimers that bind transforming growth factor-BETA1 with high affinity, avidity and specificity

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS

Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor

RECOMBINANT ANTIBODY MOLECULE AND ITS USE FOR TARGET CELL RESTRICTED T CELL ACTIVATION

FUSION PROTEINS WHICH BIND TO HUMAN FC RECEPTORS

Drug-conjugated bi-specific antigen-binding constructs

Chimeric receptors and methods of use thereof

Immunoglobulin constant region Fc receptor binding agents

Allogeneic tumor cell vaccine

Serpin fusion polypeptides and methods of use thereof

CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2

Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof

Assembly of bispecific antibodies

Subcutaneous anti-HLA-DR monoclonal antibody for treatment of hematologic malignancies

Long-acting insulin or insulin analogue conjugate

ANTI-cMET ANTIBODY

Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

Immunomodulatory fusion proteins

Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

Antibodies against CD73 and uses thereof

Methods and compositions for treatment of symptoms associated with intracranial hemorrhage

Modified gamma delta T cells and uses thereof

FLT3 directed car cells for immunotherapy

Bispecific checkpoint inhibitor antibodies

Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments

Heterodimeric antibodies that bind somatostatin receptor 2

SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION

Bispecific multivalent fusion proteins

Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer

IL15/IL15Rα heterodimeric Fc-fusion proteins

Anti-PD1 antibodies and their use as therapeutics and diagnostics

Dual specific anti-CD22-anti-CD19 chimeric antigen receptors

HOMOGENEOUS ANTIBODY POPULATIONS

OPTIMIZED CHIMERIC RECEPTOR T CELL SWITCHES AND USES THEREOF

PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS

TREATMENT WITH ANTI-EFNA4 ANTIBODY-DRUG CONJUGATES

Chimeric antigen receptors

Engineered opsonin for pathogen detection and treatment

SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES

A SOLUBLE CHIMERIC INTERLEUKIN-10 RECEPTOR AND THERAPEUTIC USE THEREOF

Multivalent Antibody Complexes Targeting IGF-1R Show Potent Toxicity Against Solid Tumors

Anti-human vista antibodies and use thereof

Monoclonal anti-GPC-1 antibodies and uses thereof

Method for producing polypeptide hetero-oligomer

Multispecific antibodies facilitating selective light chain pairing

Lysine conjugated immunoglobulins

Treatment of cancer using a CD33 chimeric antigen receptor

Polymeric Fc proteins and methods of screening to alter their functional characteristics

Modified-IgG antibodies that bind transforming growth factor-β1 with high affinity, avidity and specificity

Methods of delivering DLL3 antibody drug conjugates

Methods of making DLL3 antibody drug conjugates

Fc mutants with modified functional activity

COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS

Bispecific binding proteins and uses thereof

CEACAM6 CAR immune cells to treat cancers

Anti-DLL3 antibody drug conjugates and methods of use

Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy

Method and compositions for cellular immunotherapy

mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

ANTI-HSP70 SPECIFIC CHIMERIC ANTIGEN RECEPTORS (CARS) FOR CANCER IMMUNOTHERAPY

Anti-DLL3 antibody drug conjugates

Fusion polypeptide containing GLP and immunoglobulin hybrid Fc and use thereof

CS1 targeted chimeric antigen receptor-modified T cells

Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseases

Fc-region variants with modified FcRn- and protein A-binding properties

Modified antibody constant region

Peptide-hinge-free flexible antibody-like molecule

Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

BISPECIFIC MOLECULE BINDING TLR9 AND CD32 AND COMPRISING A T CELL EPITOPE FOR TREATMENT OF ALLERGIES

Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

GENE MODIFIED IMMUNE EFFECTOR CELLS AND ENGINEERED CELLS FOR EXPANSION OF IMMUNE EFFECTOR CELLS

Folate receptor 1 antibodies and immunoconjugates and uses thereof

MONOCLONAL ANTIBODIES AGAINST C-MET

Anti-MFI2 antibodies and methods of use

MULTIVALENT AND MULTISPECIFIC GITR-BINDING FUSION PROTEINS

Isolated nucleic acid encoding an anti-IGF-1R antibody

Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies

BISPECIFIC MOLECULE BINDING TLR9 AND CD32 AND COMPRISING A T CELL EPITOPE FOR TREATMENT OF ALLERGIES

MONOCLONAL ANTIBODIES AGAINST C-MET

RECOMBINANT ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF

Kits containing DLL3 antibody drug conjugates

Prostate-specific membrane antigen binding proteins and related compositions and methods

Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof

Anti-human vista antibodies and use thereof

Anti-human vista antibodies and use thereof

Anti-human vista antibodies and use thereof

Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease

BCMA binding molecules and methods of use thereof

ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy

Chimeric antigen receptor specific for SSEA4 antigen

Chimeric antigen and T cell receptors and methods of use

EGFRvIII Specific Chimeric Antigen Receptor For Cancer Immunotherapy

Anti-DLL3 antibody drug conjugates

Transgene genetic tags and methods of use

Immunoconjugates with an intracellularly-cleavable linkage

Anti-DLL3 antibody drug conjugates for treating cancer

Methods of making DLL3 antibody drug conjugates

Methods of delivering DLL3 antibody drug conjugates

Anti-DLL3 antibody drug conjugates

Chemically-locked bispecific antibodies

Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)

Antibodies that Bind to OX40 and Their Uses

ANTIBODIES AGAINST NERVE GROWTH FACTOR (NGF) WITH ENHANCED IN VIVO STABILITY

Production of heteromultimeric proteins using mammalian cells

Antibodies against CD73

T-cell redirecting bispecific antibodies for treatment of disease

Anti-ErbB antibodies and methods of use thereof

Immunoconjugates with an intracellularly-cleavable linkage

Heterodimeric antibody Fc-containing proteins and methods for production thereof

Chimeric antigen receptor compositions

BCMA CHIMERIC ANTIGEN RECEPTORS

MONOVALENT BINDING PROTEINS

Genetic engineering of non-human animals for the production of chimeric antibodies